Zymeworks to Acquire Theravance Biopharma for $929 Million
Question
Zymeworks to Acquire Theravance Biopharma for $929 Million
Direct answer
Consolidation in the biotech sector via cash-and-debt-funded acquisitions to acquire commercial-stage assets. — bullish pressure on TBPH via acquisition premium.
- Original publisher
- Market Ontology
- Evidence through
- 2026-06-29
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Zymeworks to Acquire Theravance Biopharma for $929 Million”, revision 1, evidence through 2026-06-29. https://marketontology.com/catalysts/2026-06-29/zymeworks-to-acquire-theravance-biopharma-for-929-million-05da74
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| TBPH | ▲Bull | Intraday | acquisition premium | 57 |
Zymeworks to Acquire Theravance Biopharma for $929 Million
Consolidation in the biotech sector via cash-and-debt-funded acquisitions to acquire commercial-stage assets. — bullish pressure on TBPH via acquisition premium.
Acquisition at $17 per share
- SourceAcquisition at $17 per share
- TransmissionConsolidation in the biotech sector via cash-and-debt-funded acquisitions to acquire commercial-stage assets.
- SummaryZymeworks gains YUPELRI for COPD treatment. The deal uses creative non-recourse financing. Theravance shareholders receive a significant premium.
- TBPHDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- TBPH closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- TBPH price vs. pre-event level
- TBPH volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
Sources
- Zymeworks to Acquire Theravance Biopharma, Inc. · news · 2026-06-29
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.